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really, I think is the million-dollar question. I believe, and correct
me if I am wrong, please, that you showed, as many other series
do, that the primary patency rates are not great, the reintervention
rate at 1 year was 20%, and I think I understood you to say that the
bypass bailout rate approached 50% at 5 years. Again, correct me if
I am wrong. If all that is true, then how has this experience inﬂu-
enced your practice in terms of decision making about the use of
infrapopliteal angioplasty vs, as you questioned in your summary
slide, going straight to a bypass?
Dr Ruby C. Lo. That’s correct. Primary patency rates were
38% and subsequent bypass was performed in 20% at 5 years.
Because of these ﬁndings, the vascular surgeons at our institutionhave been more aggressive with going straight to bypass for
patients with TASC D lesions.
Dr Cambria. 20%?
Dr Lo. Yes.
Dr Cambria.Well, that is quite similar to our own experience,
so that really is the million-dollar question as to how much to push
this as opposed to going straight to bypass.
Dr Christopher Healey (Portland, Me). I just wanted to ask
a question about how you identiﬁed the patients to analyze. Most
databases only capture patients treated with PTA by code and do
not capture those whose lesions could not be traversed. I think
patients whose lesions could not be crossed should be included to
calculate a true technical success rate. Were there patients who
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got across analyzed?
Dr Lo. Our registry included all consecutive angioplasty
procedures on an infrapopliteal vessel, so any attempt that was
made was recorded.
Dr Healey. So if no balloon was placed and no angioplasty
was done, would they get captured if you just did not cross the
lesion?
Dr Lo. No, because these charts were pulled based on proce-
dure codes. However, the point you bring up is an excellent one.
We do plan to re-query our database for tibial interventions with
the CPT modiﬁer -52, as well as review procedures pulled using
CPT codes for all diagnostic angiogram in order to capture failed
procedures we may have missed the ﬁrst time around.
Dr Cambria. He is not going to let you off the hook on that
one.
Dr Christos Liapis (Athens, Greece). Can you give us any
information from your multivariate analysis whether or not you
know which one of the arterial segments was revascularized and
whether or not this was connected with the angiosome model?
Dr Lo. We did not have sufﬁcient data about the location of
wounds in patients who presented with tissue loss, so we are
currently unable to answer this issue.
Dr Cambria. I think the answer, Christos, is that the data was
not analyzed in that manner so I do not think your question can be
answered.
Dr Firas Mussa (New York, NY). I enjoyed your presentation
and have three questions for you. One, what is your routine
approach for below-the-knee intervention? Do you just balloon,
use atherectomy, use drug-eluting or bare-metal stents? Two,
what was the fate of those who eventually needed bypass? Do
you think that you lost some ground by offering the endovascular
option ﬁrst and delaying the bypass? And last, you did not
comment on the runoff score and the number of vessels usually
present at the end of the case.
Dr Lo. To answer your ﬁrst question, stenting is not routinely
performed. It is performed for residual stenosis or for any dissec-
tion. And I believe the preferred stent they use is a non-drug-
eluting self-expandable stent.
And I am sorry, what was your second question?
Dr Mussa. So fate of those who had an open eventually.
Dr Lo. We did not assess the subsequent fate of those who
underwent a bypass after an initial angioplasty. However, this is
an interesting point and we will certainly return to our charts to
answer this question. And to answer your last question, we did
not calculate runoff scores or record the number of patent vessels
at the end of the case.
DrMichael Conte (San Francisco, Calif). I want to thank you
for updating your original report and another very thoughtful review
of your experience. And I think it conﬁrms your original ﬁndings
as you’ve pointed out on your last slide and my own biases as well.
I want to push you a little bit on multilevel disease because the
TASC classiﬁcation scheme does not capture that. You mentionedand I question your conclusion about multilevel intervention not
being an issue. I am quite sure that they are still doing a lot of
open bypass surgery at your institution, and I am asking about
the selection of patients for open vs endovascular treatment. For
those patients who had long-segment disease of more than one
segment, how many of them are in this study, or were they
more commonly treated with bypass surgery in your institution?
So how many multisegment patients are in this series?
Dr Lo. 50%.
Dr Conte. But the focus of your reports is infrapopliteal
angioplasty, so what was the extent of disease in the other
segments, were they relatively straightforward TASC A and B
SFA lesions, or did you preferably bypass patients with TASC C
and D femoropopliteal disease who also had tibial lesions?
Dr Lo. Unfortunately, we did not record the TASC classes of
concurrently treated femoral and popliteal lesions, so I cannot
comment about how severe the disease was in those patients
undergoing multilevel intervention.
Dr Carl Wahlgren (Stockholm, Sweden). What was your
protocol for antiplatelet therapy, and did that protocol change
during the study period?
Dr Lo. The practice at our institution has been to load
patients with Plavix after the case and then patients are put on Pla-
vix for at least 30 days and aspirin indeﬁnitely thereafter, unless
there is contraindication or if a bypass is planned in the immediate
future.
Dr Gregory Moneta (Portland, Ore). I was going to ask
a question about the other end of the spectrum that Dr Conte
asked about. You had a number of patients that apparently had
focal lesions in their tibial vessels. It is probably impossible to
answer, but I wonder how many of your patients might have
done just ﬁne with good wound care and no catheter-based inter-
vention but were treated because of the availability of this
technology?
Dr Lo. I think that is a very good question but, as you
mentioned, impossible to answer, since this study was retrospective
in nature.
Dr Cambria. I do not think the question is answerable from
Dr Lo’s data.
Dr Carlo Dall’Olmo (Flint, Mich). Just a comment. I want
to compliment the authors. But I wanted to mention that in
the new health care legislation, this data is absolutely critical in
terms of approaching critical limb ischemia, because one of the
things that will happen is that we will be graded on resource utili-
zation. There will be a public website that the patients in this
country can address and it will grade us on our utilization, and
utilization will have an impact on reimbursement. That is why
this information is so critical because the less you use, the better
off you will be. And the days of using multiple and performing
multiple procedures will be used against and graded against the
surgeon. We will have a lot to say about that Saturday morning
in the health care symposium we have, so I would encourage
all to attend.
